Benjamin M. Greenberg, MD, MHS&Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach - a podcast by PVI, PeerView Institute for Medical Education

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Further episodes of PeerView Family Medicine

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education